This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Potential Agent for Treating Narcotic Addiction

Donald R. Jasinski, MD; Jeffrey S. Pevnick, MD; John D. Griffith, MD

Arch Gen Psychiatry. 1978;35(4):501-516.

Abstract
• Buprenorphine was evaluated for its abuse potential and utility in treating narcotic addiction. The drug was morphine-like but was 25 to 50 times more potent than morphine and was longer-acting. Little if any physical dependence of clinical significance was produced by buprenorphine. The effects of morphine to 120-mg doses were blocked by buprenorphine, a blockade that persisted for 291/2 hours. In man, buprenorphine has less intrinsic activity than morphine, and as such, has a low abuse potential. Moreover, the drug has potential for treating narcotic addiction since it is acceptable to addicts, is long-acting, produces a low level of physical dependence such that patients may be easily detoxified, is less toxic than drugs used for maintenance therapy, and blocks the effects of narcotics.

Author Affiliations
From the National Institute on Drug Abuse, Division of Research, Addiction Research Center, Lexington, Ky. Dr Pevnick is now with St Louis State Hospital.

Footnotes
Accepted for publication Oct 15, 1977.

Reprint requests to National Institute on Drug Abuse, Addiction Research Center, PO Box 12390, Lexington, KY 40583 (Dr Jasinski).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Extended vs Short-term Buprenorphine-Naloxone for Treatment of Opioid-Addicted Youth: A Randomized Trial
Woody et al.
JAMA 2008;300:2003-2011.
ABSTRACT | FULL TEXT  

SR 16435 [1-(1-(Bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a Novel Mixed Nociceptin/Orphanin FQ/{micro}-Opioid Receptor Partial Agonist: Analgesic and Rewarding Properties in Mice
Khroyan et al.
J. Pharmacol. Exp. Ther. 2007;320:934-943.
ABSTRACT | FULL TEXT  

Clinical Advances in Pharmacological and Integrated Treatment Approaches for Alcohol and Drug Use Disorders
Dermatis and Galanter
Focus 2007;5:141-150.
ABSTRACT | FULL TEXT  

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
Gonzales et al.
JAMA 2006;296:47-55.
ABSTRACT | FULL TEXT  

Pharmacokinetics and Pharmacodynamics of Multiple Sublingual Buprenorphine Tablets in Dose-Escalation Trials
Ciraulo et al.
J Clin Pharmacol 2006;46:179-192.
ABSTRACT | FULL TEXT  

Comparison of Intravenous Buprenorphine and Methadone Self-Administration by Recently Detoxified Heroin-Dependent Individuals
Comer et al.
J. Pharmacol. Exp. Ther. 2005;315:1320-1330.
ABSTRACT | FULL TEXT  

Comparison of Pharmacological Treatments for Opioid-Dependent Adolescents: A Randomized Controlled Trial
Marsch et al.
Arch Gen Psychiatry 2005;62:1157-1164.
ABSTRACT | FULL TEXT  

Medication Development for Addictive Disorders: The State of the Science
Vocci et al.
Am. J. Psychiatry 2005;162:1432-1440.
ABSTRACT | FULL TEXT  

Pharmacokinetic-Pharmacodynamic Modeling of the Antinociceptive Effect of Buprenorphine and Fentanyl in Rats: Role of Receptor Equilibration Kinetics
Yassen et al.
J. Pharmacol. Exp. Ther. 2005;313:1136-1149.
ABSTRACT | FULL TEXT  

Treating Opioid Dependence: Growing Implications for Primary Care
Krantz and Mehler
Arch Intern Med 2004;164:277-288.
ABSTRACT | FULL TEXT  

Buprenorphine-Induced Antinociception Is Mediated by {micro}-Opioid Receptors and Compromised by Concomitant Activation of Opioid Receptor-Like Receptors
Lutfy et al.
J. Neurosci. 2003;23:10331-10337.
ABSTRACT | FULL TEXT  

Management of Drug and Alcohol Withdrawal
Kosten and O'Connor
NEJM 2003;348:1786-1795.
FULL TEXT  

Transplacental Transfer and Metabolism of Buprenorphine
Nanovskaya et al.
J. Pharmacol. Exp. Ther. 2002;300:26-33.
ABSTRACT | FULL TEXT  

Effects of Infusion Rate of Intravenously Administered Morphine on Physiological, Psychomotor, and Self-Reported Measures in Humans
Marsch et al.
J. Pharmacol. Exp. Ther. 2001;299:1056-1065.
ABSTRACT | FULL TEXT  

Office-Based Treatment for Opioid Dependence: Reaching New Patient Populations
Fiellin et al.
Am. J. Psychiatry 2001;158:1200-1204.
FULL TEXT  

Buprenorphine: "Field Trials" of a New Drug
Agar et al.
Qual Health Res 2001;11:69-84.
ABSTRACT  

A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson et al.
NEJM 2000;343:1290-1297.
ABSTRACT | FULL TEXT  

Pharmacologic Treatment of Heroin-Dependent Patients
O'Connor and Fiellin
ANN INTERN MED 2000;133:40-54.
ABSTRACT | FULL TEXT  

14-Methoxymetopon, A Potent Opioid, Induces No Respiratory Depression, Less Sedation, and Less Bradycardia than Sufentanil in the Dog
Freye et al.
Anesth. Analg. 2000;90:1359-1364.
ABSTRACT | FULL TEXT  

Assessment of Opioid Partial Agonist Activity with a Three-Choice Hydromorphone Dose-Discrimination Procedure
Jones et al.
J. Pharmacol. Exp. Ther. 1999;289:1350-1361.
ABSTRACT | FULL TEXT  

Human Buprenorphine N-Dealkylation Is Catalyzed by Cytochrome P450 3A4
Kobayashi et al.
Drug Metab. Dispos. 1998;26:818-821.
ABSTRACT | FULL TEXT  

Subnanogram-concentration measurement of buprenorphine in human plasma by electron-capture capillary gas chromatography: application to pharmacokinetics of sublingual buprenorphine
Everhart et al.
Clin. Chem. 1997;43:2292-2302.
ABSTRACT | FULL TEXT  

Comparing the Subjective, Psychomotor and Physiological Effects of Intravenous Buprenorphine and Morphine in Healthy Volunteers
Zacny et al.
J. Pharmacol. Exp. Ther. 1997;282:1187-1197.
ABSTRACT | FULL TEXT  

Discriminative Stimulus Effects of l-alpha -Acetylmethadol (LAAM), Buprenorphine and Methadone in Morphine-Treated Rhesus Monkeys
Brandt et al.
J. Pharmacol. Exp. Ther. 1997;282:574-584.
ABSTRACT | FULL TEXT  

Buprenorphine vs Methadone Maintenance Treatment for Concurrent Opioid Dependence and Cocaine Abuse
Schottenfeld et al.
Arch Gen Psychiatry 1997;54:713-720.
ABSTRACT  

A Controlled Trial Comparing Buprenorphine and Methadone Maintenance in Opioid Dependence
Ling et al.
Arch Gen Psychiatry 1996;53:401-407.
ABSTRACT  

A Controlled Trial of Buprenorphine Treatment for Opioid Dependence
Johnson et al.
JAMA 1992;267:2750-2755.
ABSTRACT  

Review article : Opioid analgesics in the management of pain in patients with cancer. A review
Hanks and Hoskin
Palliat Med 1987;1:1-25.